Girentuximab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric |
| Target | CA-IX |
| Clinical data | |
| Trade names | Rencarex |
| Identifiers | |
| CAS Number | 916138-87-9  |
| ATC code | none |
| UNII | 539B57DFJF  |
| Chemical data | |
| Formula | C6460H10006N1718O2018S48 |
| Molecular mass | 146.5 kg/mol |
| (what is this?) (verify) |
|
Girentuximab (trade name Rencarex) is a chimeric monoclonal antibody to carbonic anhydrase IX.[1] It is investigational agent in clinical trials for renal cell carcinoma.[2]
Girentuximab was developed by Wilex AG.
It triggers antibody-dependent cell-mediated cytotoxicity (ADCC). It does this by activating natural killer cells by binding to carbonic anhydrase IX.[3]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Girentuximab (Rencarex) for renal cell carcinoma
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibodies
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
